Disc Medicine, Inc.
NASDAQ:IRONBiotechnology
-$0.02 today
- Market cap
- $2.92B
- Beta
- 2.10
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$6.28
Volume 0.65M
Average 0.47M
Returns on capital
Disc Medicine, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.7%
avg 23.5%
ROIC
-30.6%
avg -4322.6%
ROA
-26.3%
avg -103.7%
Analysis
ROA is currently the strongest return metric at -26.3% versus its period average of -103.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
John D. Quisel | Chief Executive Officer, President & Director | USD 1.26M | 55 | 150.12K | 0.39% |
Jean Franchi | Chief Financial Officer | USD 838.98K | 60 | — | — |
William Jacob Savage | Chief Medical Officer | USD 836.84K | 52 | 63.45K | 0.17% |
Pamela Stephenson | Chief Commercial Officer | USD 832.1K | 58 | 81.00K | 0.21% |
Jonathan Yu | Chief Opearating Officer | USD 811.56K | 45 | — | — |
Donald William Nicholson | Executive Chairman | USD 170K | 69 | 6.21K | 0.02% |
Brian MacDonald | Founder & Chair of Scientific Advisory Board | USD 88.54K | 65 | — | — |
Rahul Rajan Kaushik | Chief Technical Officer | — | — | — | — |
Srikanth Venkatraman | Senior Vice President & Head of Chemistry | — | — | — | — |
Lisa Amaya Price | Chief Human Resources Officer | — | — | — | — |
Rahul Khara | Chief Legal Officer & Secretary | — | 44 | 49.80K | 0.13% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
96
$48.75M
Net Transaction Value
−$48.75M
Net selling
Most Active
Bitterman Kevin
47 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 10, 26Nov 10, 2026 | Savage William Jacob Direct | Sell | $1.4M$1,364,437.39 |
| Oct 21, 26Oct 21, 2026 | Bitterman Kevin Indirect | Sell | $21.3K$21,341.18 |
| Oct 21, 26Oct 21, 2026 | Bitterman Kevin Indirect | Sell | $1.1M$1,105,810.09 |
| Oct 21, 26Oct 21, 2026 | Bitterman Kevin Indirect | Sell | $920.2K$920,238.10 |
| Oct 20, 26Oct 20, 2026 | Bitterman Kevin Indirect | Sell | $229.4K$229,376.55 |
| Oct 20, 26Oct 20, 2026 | Bitterman Kevin Indirect | Sell | $190.9K$190,920.60 |
| Oct 20, 26Oct 20, 2026 | Bitterman Kevin Indirect | Sell | $4.4K$4,397.25 |
| Oct 19, 26Oct 19, 2026 | Bitterman Kevin Indirect | Sell | $395.2K$395,211.74 |
| Oct 19, 26Oct 19, 2026 | Bitterman Kevin Indirect | Sell | $9.2K$9,196.55 |
| Oct 19, 26Oct 19, 2026 | Bitterman Kevin Indirect | Sell | $474.8K$474,781.89 |
1–10 of 96
Summary
Insiders reported 0 buys worth $0.00 and 96 sells worth $48.75M over the last 12 months. That adds up to net selling of $48.75M. Bitterman Kevin was the most active insider with 47 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Disc Medicine, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about IRON's management, answered from reported figures.
Who manages IRON?
Disc Medicine, Inc. (IRON) lists 11 active executives. The top listed executive is Brian MacDonald, Founder & Chair of Scientific Advisory Board.
Are IRON insiders buying or selling?
Recent insider activity shows net selling of $105.57M.
Continue the stock analysis
Jump to another research area for this company.